Across TCGA pan-cancer cohorts, CCDC122 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCDC122 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CCDC122 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CCDC122 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, COAD, and STAD are the cancer types where CCDC122 Mutation most reproducibly stratifies survival.